Credit: iStock
Flu cases are rising earlier than usual in the US, with influenza A H1N1 driving most infections. A new mutation, G155E, may be contributing to the surge.
The 2026-2027 flu season began earlier than usual, with infections increasing as early as August. As of November 5, flu activity was growing or likely growing in 42 states, according to the US Centers for Disease Control and Prevention (CDC).
At least 1.7 million illnesses, 25,000 hospitalisations and 1,400 deaths have been reported so far this season.
“Early-season influenza activity is currently higher than typically observed at this time of year,” the CDC said in its FluView report for the week ending October 31.
Also read: G155E H1N1 Mutation In US Raises Concerns: Can This Year’s Flu Shot Still Protect You?
H1N1 is currently responsible for the vast majority of flu cases, marking a shift from last winter, when influenza A H3N2 subclade K, also known as the “superflu”, dominated.
The circulating H1N1 strain has acquired a new mutation called G155E. Early laboratory findings suggest it may make some strains harder for existing antibodies to recognise, potentially helping the virus evade immunity from previous infections or vaccination.
“It is different from last year’s H1N1 virus, and that mutation position (G155E) we know is important for generating protective antibody responses,” Andrew Pekosz, PhD, a virologist at the Johns Hopkins Bloomberg School of Public Health, told TODAY.com.
However, it is not yet clear whether the mutation is contributing to the early surge or making infections more severe.
“How that (mutation) is going to affect the disease spread and severity is not clear,” Pekosz said.
READ: Flu Activity Rises Early In US, UK And Japan: Why Experts Urge Vaccination Before Winter
The impact of G155E on vaccine effectiveness remains uncertain. The CDC said it was too early to determine whether the mutation would affect protection this season.
The 2026-2027 flu vaccines target three viruses: influenza A H1N1 (pdm09), influenza A H3N2 and influenza B.
Even if the circulating H1N1 strain differs from the vaccine strain, vaccination can still protect against severe illness and other circulating flu viruses.
“Even if there’s a mismatched strain, there’s two other strains that the vaccine will provide better protection against,” Pekosz said.
The American Medical Association recommends annual flu vaccination for everyone aged six months and older, unless medically contraindicated.
Read More: Flu 2026: Symptoms To Watch For As New Season Begins
Common symptoms include:
Flu symptoms can overlap with those of COVID-19, making testing important.
Antiviral medications can help reduce the severity and duration of influenza, particularly among people at higher risk of complications, including adults over 65, children under five, and immunocompromised individuals.
“You have to get that prescription fast ... within the first 48 hours after symptom onset, (or else) they don’t work as well,” Pekosz said.
Experts say the emergence of G155E is not a reason to panic but reinforces the importance of flu vaccination.
“View (this) as a sign to go out and get the flu vaccine,” Pekosz said.
It takes approximately two weeks for vaccine-induced protection to develop. Annual vaccination remains an important way to reduce the risk of severe flu, complications and hospitalisation. Regular hand hygiene can also help limit the spread of infection.
Flu and COVID-19 vaccines target different viruses. A flu shot does not protect against COVID-19, so eligible people may need separate vaccinations to reduce their risk of severe illness from both infections.
“Flu vaccination doesn't protect just yourself against the risk of having influenza but it also prevents transmission of infection to other vulnerable people around ourselves like little ones, elderly family members and people with medical conditions,” Dr. Bhawna Malik, Senior Consultant-Neonatologist and Pediatric Intensivist at Motherhood Hospitals, Greater Noida, told HealthandMe.
Credit: AI Image
The US has lost its measles elimination status after 26 years, with Bolivia and Mexico also losing the designation, the Pan American Health Organization (PAHO) announced on Tuesday. The decision follows more than 12 months of continuous measles transmission in the US.
Amid the resurgence, a CDC-led report has identified 112 measles infections among pregnant women in the US between January 2025 and September 2026, along with 13 cases of congenital measles in newborns. Nearly all the women were unvaccinated or had an unknown vaccination status.
The actual number of infections among pregnant women may be higher. A separate CIDRAP News investigation based on state health department data identified at least 167 pregnant women infected in 2025 and 2026.
Also Read: What Happens After Measles Infection? The Hidden Risks That Can Last For Years
The CDC-led report, published in NEJM Evidence journal, found that 108 (96%) of the 112 cases occurred during outbreaks involving 50 or more cases.
Of the infected women, 110 (98%) had received no MMR vaccine doses or had an unknown vaccination status.
Twenty-six women (23%) were hospitalized for reasons unrelated to childbirth, while 11 (10%) developed pneumonia.
“Even though measles is an old disease, measles in pregnancy is an emerging area that we need to learn about,” said Michelle Barton, a professor at the Schulich School of Medicine & Dentistry at Western University.
Read More: Congenital Measles Reported In Pennsylvania For First Time In Decades: What Parents Should Know
The report recorded 21 pregnancy outcomes within 14 days of maternal rash onset: 19 live births and two pregnancy losses, including one miscarriage and one stillbirth.
Eight babies were born prematurely, and eight required admission to a neonatal intensive care unit (NICU).
The report noted that 13 babies had congenital measles and tested positive for the virus. Of these, six developed symptoms, including one with signs compatible with meningoencephalitis, a potentially life-threatening inflammation of the brain and surrounding membranes.
The authors said the outbreaks highlighted measles' risks to maternal and newborn health.
Many doctors and nurses treating these patients have never encountered measles, relying largely on medical training and professional guidelines to manage the infections.
The CDC recommends intravenous immunoglobulin as post-exposure prophylaxis for pregnant women without documented MMR vaccination or other evidence of immunity who are exposed to measles.
Newborns exposed to measles in the womb should also receive immunoglobulin at birth. Congenital measles can cause severe neurological complications, including subacute sclerosing panencephalitis (SSPE), a rare, progressive brain disorder.
The US is experiencing its highest measles burden in more than three decades. Since 2025, approximately 7,700 people have been infected and 13 have died, according to the figures cited in the report.
As of November 12, the CDC had confirmed 5,412 cases and six deaths in 2026. States had reported 10 deaths.
The rise in infections has coincided with declining vaccination rates and growing vaccine hesitancy. US Health Secretary Robert F. Kennedy Jr. has repeatedly questioned measles vaccine safety without scientific evidence supporting those claims.
The CDC said it would work to stop outbreaks and regain elimination status by supporting states and providing sustained national leadership.
"The measles elimination designation is not what protects Americans; vaccination does," CDC Director Erica Schwartz said.
Credit: AI Image
A new trial by Novo Nordisk found that Wegovy (semaglutide) reduced body mass index (BMI) by at least 10% in nearly 80% of children with obesity aged 6 to under 12 years.
The phase 3 STEP Young trial found that 78.7% of children receiving semaglutide achieved this reduction after 68 weeks, compared with none in the placebo group.
However, the findings raise questions about the safety of GLP-1 medications in younger children. The World Health Organization (WHO) does not recommend weight-loss medicines for treating obesity in children under 10, citing limited evidence on their long-term safety and effectiveness.
Also read: Wegovy & Zepbound Are Not Approved By US FDA For Children Under 12: So Why Are Prescriptions Rising?
The phase 3 trial evaluated once-weekly semaglutide injections in children aged 6 to under 12 with obesity. Participants also followed a reduced-calorie diet and increased their physical activity.
The findings were presented at ObesityWeek 2026 and published in The New England Journal of Medicine.
After 68 weeks:
Childhood obesity increases the risk of type 2 diabetes, high blood pressure, abnormal cholesterol levels and obstructive sleep apnea. Severe obesity can also affect a child's physical health, emotional well-being and daily life, with complications that may persist into adulthood.
The trial also found improvements in multiple cardiometabolic measures among children receiving semaglutide.
"Encouragingly, treating obesity with semaglutide was accompanied by improvements in multiple cardiometabolic measures, suggesting that effective treatments for severe childhood obesity may shift a child's trajectory back towards one of improving weight-related health," said Ania M. Jastreboff, Professor of Medicine and Pediatrics at Yale School of Medicine and Director of the Yale Obesity Research Center.
What Are The Side Effects?
Read More: Are GLP-1 Drugs Safe for Children? Study Finds Nutritional Deficiency in Nearly 17% Within a Year
Adverse events were reported in 96% of children receiving semaglutide and 93% receiving placebo. Gastrointestinal problems were the most common and occurred more frequently among children taking the drug.
Common gastrointestinal side effects associated with semaglutide include nausea, vomiting, diarrhoea, constipation and abdominal pain.
Other potential risks associated with GLP-1 treatment include gallbladder problems, pancreatitis and dehydration.
The WHO does not recommend weight-loss medicines, bariatric surgery or weight-management devices for children aged 0 to 9, as there is insufficient evidence on GLP-1 drugs in younger populations.
Instead, it recommends healthy eating, physical activity and behavioural support for children and their caregivers.
For adolescents aged 10 to 19, approved obesity medicines may be considered alongside structured lifestyle interventions.
Read More: Childhood Obesity In India To Surge To 56 Million By 2040, Says Global Report
Despite these recommendations, GLP-1 prescriptions among younger children in the US are rising.
A NYU Langone Health study analysing health records of more than 3.5 million children found that prescriptions among those aged 8 to 11 with obesity increased more than 300-fold between 2019 and June 2026.
The GLP-1 medications approved for adolescents by the US FDA are not necessarily approved for children under 12.
However, a study from Northwestern University and Ann & Robert H. Lurie Children's Hospital of Chicago flagged nutritional deficiencies among young children taking GLP-drugs.
It showed that 16.8% of children aged 10 to 17 receiving GLP-1 medications developed a nutritional deficiency within a year. Vitamin D deficiency was the most common, affecting 12.4% of patients.
Amid limited long-term safety data, experts are concerned about prescribing appetite-suppressing drugs to children who are still growing, particularly because reduced appetite could lead to inadequate calorie and nutrient intake.
Credit: Health Ministry/X
Malaria cases and deaths in India declined by nearly 80% between 2015 and 2025, President Droupadi Murmu said on Tuesday, while warning that climate change, unplanned urbanization and growing mosquito resistance could create new challenges for malaria elimination.
Speaking at the inauguration of the Golden Jubilee celebrations of the Indian Council of Medical Research–National Institute of Malaria Research (ICMR–NIMR), the President called for sustained vigilance, stronger surveillance and greater community participation to achieve malaria elimination.
The President noted that malaria remains a serious public health challenge in several countries, including India.
Recalling the situation at the time of independence, she said the vector-borne disease was among the country's most critical public health challenges. She also shared her personal observations of how malaria affected people's lives.
"During the monsoon season, fever was often accepted as an inevitable hardship of life. Children were unable to attend school, while farmers and laborers were often left unable to work for days on end. For the people, malaria was not merely a health issue—it was deeply intertwined with their livelihoods, education, and future," she said.
India has since made significant progress through sustained public health interventions. Between 2015 and 2025, malaria cases and deaths declined by nearly 80%, while the number of high-burden districts fell from 155 to 33.
As many as 160 districts reported zero indigenous malaria cases between 2022 and 2025, reflecting progress in interrupting local transmission and implementing targeted malaria control and elimination measures.
Calling the progress "remarkable", the President credited improved healthcare services, modern diagnostic techniques, effective medicines, mosquito-control campaigns and community participation for curbing the disease.
Also read: El Niño Could Worsen Dengue, Malaria And Heat Illness: Why WHO Declared A Health Emergency
Despite the progress, malaria remains a challenge in certain regions, the President said, stressing the need for "sustained vigilance and effective efforts" to eliminate the disease.
She highlighted the importance of robust systems for malaria testing, treatment, surveillance and mosquito control.
Research aimed at developing new drugs and vaccines, along with public awareness and community participation, will also be vital for malaria elimination, she said.
The President warned that climate change, unplanned urbanization and growing mosquito resistance to insecticides could create new obstacles to malaria elimination efforts.
She also urged citizens to contribute to prevention efforts by avoiding water stagnation, eliminating mosquito breeding sites and maintaining a clean environment.
Beyond malaria, she noted that rising global temperatures and shifting monsoon patterns are further intensifying the challenge posed by dengue.
Addressing the gathering, Union Minister of Health and Family Welfare Jagat Prakash Nadda said India's progress in malaria control over the past decade was the result of a comprehensive approach involving research on mosquito behaviour and malaria parasites, community participation, effective prevention, early diagnosis and appropriate treatment.
Highlighting India's progress in malaria control, Nadda noted that the country, which accounts for approximately 16% of the global population, contributes around 0.7% of global malaria cases and 0.6% of malaria deaths.
The Union Minister also appreciated India's exit from the WHO's High Burden to High Impact initiative and expressed confidence in achieving malaria elimination by 2030.
"We will eliminate malaria by 2030 by bringing about the necessary changes in our strategies and policies," he said, calling upon ICMR–NIMR to work with renewed commitment.
The Minister also highlighted ICMR's contributions to medical innovation, including MedTech Mitra, Patent Mitra and ELISA-based molecular diagnostics for dengue, chikungunya, Japanese encephalitis and other infectious diseases.
© $2026 Times Horizon Private Limited